Sarah Alspach is Executive Vice President and Chief Communications Officer at BIO. In this role, Sarah oversees BIO’s efforts to tell the stories of biotechnology and the power of the biotech industry to change lives and improve communities in the US and around the world.
Sarah joined BIO in 2024 from bluebird bio, one of the world's leading gene therapy companies. While at bluebird, Sarah oversaw external affairs – including corporate communications, government affairs and patient advocacy – for the FDA approval and launch of three gene therapies, including a first-of-its-kind therapy for sickle cell disease.
Prior to joining bluebird, Sarah served as Senior Vice President and Chief Communications Officer for the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis and pioneer of the venture philanthropy model. At the CF Foundation, Sarah was accountable for communications spanning research and clinical care, policy and advocacy, internal and executive communications, media relations, digital marketing and the Foundation brand.
Sarah also spent more than 10 years at GSK where she was Vice President for U.S. Pharma and Corporate Communications, overseeing U.S. external communications, internal communications, digital and visual communications, brand activation, and GSK’s U.S. philanthropic giving. She also served as the primary communications point of contact for issues related to pharmaceuticals and vaccines, drug pricing, government affairs, and public policy.
Sarah holds a B.S. in public relations from the University of Texas at Austin.